Diabetes

October 3, 2017

Molecular therapy for TIIDM and obesity-associated metabolic deficits: Milnacipran, a serotonin norepinephrine reuptake inhibitor,  increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM via down regulation of its target gene, 4/October/2017, 2.39 am

Introduction: What they say A study from the Department of Physiology-Cellular Biophysics, College of Physicians and Surgeons, Columbia University, New York, New York, USA shows that […]
October 3, 2017

Natural product-based combinatorial therapy for TIIDM, Metabolic defects and Longevity: A therapeutic mix encompassing Nordihydroguaiaretic acid (NDGA) & Mangosteen  (NDGAM) increases Sirtuin-4 expression, augments insulin secretion, reduces metabolic stress, improves glucose uptake, promotes glucose homeostasis and prevents progression to TIIDM via down regulation of its target gene, 04/October/2017, 1.53 am

Introduction: What they say A study from the “Duke Molecular Physiology Institute and Sarah W. Stedman Nutrition and Metabolism Center, Duke University Medical Center, Durham, NC […]
October 1, 2017

Natural product-derived regenerative therapy for reversing diabetes: a therapeutic mix encompassing Berberine, Leucine, and Genistein (BLG) increases the expression of Sox17, Sox2, Pdx-1, and Ngn3, decreases mTOR expression, promotes regeneration of insulin-producing ß cells, increases insulin secretion, promotes glucose homeostasis and reverses T1D and T2D via down regulation of its target gene, 2/October/2017, 12.14 am

Introduction: What they say A study from the Longevity Institute, School of Gerontology, Department of Biological Sciences, University of Southern California, 3715 McClintock Avenue, Los Angeles, […]
October 1, 2017

Antidepressant-based therapy for Metabolic diseases: Fluoxetine, an anti-depressant drug, increases the expression of Caveolin-1, stabilizes insulin receptor, promotes insulin sensitivity, incrases vasorelaxation, and decreases the risk of hyperglycemia and TIIDM via up regulation of its target gene.., 1/October/2017, 11.51 pm

Introduction: What they say A study from the Institute for Molecular Systems Biology, ETH Zurich, Zurich, Switzerland shows that “MicroRNAs 103 and 107 regulate insulin sensitivity.” This study was published in the June […]